Anti-GFPT1 antibody [EPR4854] (ab125069)

Overview

  • Product nameAnti-GFPT1 antibody [EPR4854]
    See all GFPT1 primary antibodies
  • Description
    Rabbit monoclonal [EPR4854] to GFPT1
  • Tested applicationsSuitable for: WB, IP, IHC-Pmore details
    Unsuitable for: Flow Cyt or ICC
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide corresponding to residues in Human GFPT1.

  • Positive control
    • Human testis tissue; Human placenta lysate, 293T, JAR and HeLa cell line lysates.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

Properties

Applications

Our Abpromise guarantee covers the use of ab125069 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Detects a band of approximately 79 kDa (predicted molecular weight: 79 kDa).
IP 1/10 - 1/100.
IHC-P 1/100 - 1/250. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
  • Application notesIs unsuitable for Flow Cyt or ICC.
  • Target

    • FunctionControls the flux of glucose into the hexosamine pathway. Most likely involved in regulating the availability of precursors for N- and O-linked glycosylation of proteins.
    • Tissue specificityIsoform 1 is predominantly expressed in skeletal muscle. Not expressed in brain. Seems to be selectively expressed in striated muscle.
    • PathwayNucleotide-sugar biosynthesis; UDP-N-acetyl-alpha-D-glucosamine biosynthesis; alpha-D-glucosamine 6-phosphate from D-fructose 6-phosphate: step 1/1.
    • Involvement in diseaseDefects in GFPT1 are the cause of limb-girdle myasthenia with tubular aggregates (LGMTA) [MIM:610542]. A congenital myasthenic syndrome characterized by onset of proximal muscle weakness in the first decade. Individuals with this condition have a recognizable pattern of weakness of shoulder and pelvic girdle muscles, and sparing of ocular or facial muscles. EMG classically shows a decremental response to repeated nerve stimulation, a sign of neuromuscular junction dysfunction. Affected individuals show a favorable response to acetylcholinesterase (AChE) inhibitors.
    • Sequence similaritiesContains 1 glutamine amidotransferase type-2 domain.
      Contains 2 SIS domains.
    • Information by UniProt
    • Database links
    • Alternative names
      • CMSTA1 antibody
      • D-fructose-6-phosphate amidotransferase 1 antibody
      • GFA antibody
      • GFAT 1 antibody
      • GFAT antibody
      • GFAT1 antibody
      • GFAT1m antibody
      • GFPT antibody
      • Gfpt1 antibody
      • GFPT1_HUMAN antibody
      • GFPT1L antibody
      • Glucosamine--fructose-6-phosphate aminotransferase [isomerizing] 1 antibody
      • Glutamine--fructose-6-phosphate transaminase 1 antibody
      • Glutamine:fructose 6 phosphate amidotransferase 1 antibody
      • Hexosephosphate aminotransferase 1 antibody
      • MSLG antibody
      see all

    Anti-GFPT1 antibody [EPR4854] images

    • ab125069, at a 1/100 dilution, staining GFPT1 in paraffin-embedded Human testis tissue by immunohistochemistry.
    • All lanes : Anti-GFPT1 antibody [EPR4854] (ab125069) at 1/1000 dilution

      Lane 1 : 293T cell lysate
      Lane 2 : JAR cell lysate
      Lane 3 : HeLa cell lysate
      Lane 4 : Human placenta lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      Goat anti-Rabbit HRP at 1/2000 dilution
      Developed using the ECL technique

      Predicted band size : 79 kDa

    References for Anti-GFPT1 antibody [EPR4854] (ab125069)

    ab125069 has not yet been referenced specifically in any publications.

    Product Wall

    Application Western blot
    Sample Human Cell lysate - whole cell (HBEC cells)
    Gel Running Conditions Reduced Denaturing (10%)
    Loading amount 20 µg
    Treatment glucose deprivation
    Specification HBEC cells
    Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
    Username

    Abcam user community

    Verified customer

    Submitted Jun 08 2016

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"